Basaran, G. Et Al. 2010. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?. JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27 .

Basaran, G., Agaoglu, F., & Basaran, M., (2010). Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?. JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27.

Basaran, Gul, Fulya AĞAOĞLU, And Mert BAŞARAN. "Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?," JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27, 2010

Basaran, Gul Et Al. "Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?." JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27, 2010

Basaran, G. Agaoglu, F. And Basaran, M. (2010) . "Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?." JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27.

@article{article, author={Gul Basaran Et Al. }, title={Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2010}